stable angina pectoris of coronary heart disease
Conditions
Interventions
Experimental group:Guanxin Qiwei dropping pill
Control group:compound danshen dropping pill
Sponsors
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients with stable angina pectoris of coronary heart disease (Class I or II); 2. Evidence of stable angina pectoris of coronary heart disease of a well-documented medical history (over 3 months prior to the enrolment), and attacked within a month; 3. Patients with one of the followings: (1) Coronary angiography showed over 50% of coronary artery stenosis; (2) Coronary CT showed over 50% of coronary artery stenosis; (3) Have a history of Myocardial infarction. 4. TCM pattern diagnosis of blood stasis syndrome; 5. Males and females between the ages of 18 and 70 years; 6. Females of childbearing potential must have a negative pregnancy test, and must agree to remain on their established method of contraception through their participation in the study and for 14 days following the last dose of study drug; 7. Written informed consent.
Exclusion criteria
Exclusion criteria: 1. patients with Acute coronary syndrome(ST segment elevation myocardial infarction, Non ST segment elevation myocardial infarction, Unstable angina pectoris), Silent myocardial ischemia, Ischemic cardiomyopathy or Miocardial infarction 3 months before trial; 2. patients with Rheumatic heart disease, Hyperthyroidism heart disease, Hypertensive heart disease, Myocarditis, Non coronary atherosclerotic heart disease such as Cardiomyopathy; 3. patients with Cervical spondylosis, Menopausal syndrome, Biliary syndrome, Reflux of stomach and esophagus, Non coronary heart disease caused by chest pain and neurosis such as Aortic dissection; 4. patients with Acute cerebral infarction and cerebral hemorrhage; 5. Patients who complicate severe heart, lung, liver (blood AST, ALT higher than 1.5 times of upper limited ) renal failure; Severe primary diseases such as hematopoietic system and endocrine system; malignant tumors; gastrointestinal bleeding; gastric ulcer; bleeding tendency; 6. patients with severe uncontrolled hypertension (seated systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg); 7. patients with clinically significant arrhythmias, including bigeminy coupled rhythm, ventricular tachycardial, ventricular fibrillation, complete atrioventricular block, arrest, severe sinus bradycardia, Sick Sinus Syndrome, arrhythmias of hemodynamic changes caused by reentry supraventricular tachycardia; 8. patients with acute or chronic heart failure patients with III or IV cardiac function; 9. Patients with Class III or IV, Grading of Angina Pectoris by the Canadian Cardiovascular Society Classification System(CCS); 10. Participation in any other clinical trial or receipt of an investigational drug within 30 days prior to the initial visit; 11. patients with glaucoma; 12. Pregnancy, childbearing potential or lactation women; 13. psychopaths; 14. Males and females younger than 18 years or older than 70 years; 15. patients with hypersensitivity or allergic to several medicine; 16. Unfit to inclusion criteria; 17. Unwilling to cooperate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Angina symptoms; | — |
Countries
China
Contacts
Public ContactChen Min
Outcome results
None listed